Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
Durvalumab
United Therapeutics Europe Ltd
Stage IB Hepatocellular Carcinoma AJCC v8
1 trial -
Durvalumab
Syndax Pharmaceuticals
Unresectable Intrahepatic Cholangiocarcinoma
1 trial -
Durvalumab + Oleclumab
MedImmune
Stage III Non-small Cell Lung Cancer
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
HPV-Associated Cervical Carcinoma
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
Cervical Cancer
1 trial -
E7080
Eisai Co.,
Solid Tumors
1 trial -
E7090
Eisai Co.,
Cholangiocarcinoma
1 trial -
E7386-G000-201
Eisai Co.,
colorectal cancer, melanoma, hepatocellular carcinoma
1 trial -
E7386-J081-102
Eisai Co.,
Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor
1 trial -
EBV-TCR-T (YT-E001) cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
EBV-specific T cells (EBV-CTLs)
Evidence Based Cataract Study Group
EBV-induced Lymphomas
1 trial -
EBVALLO
Pierre Fabre Medicament
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
1 trial -
EDGE-Lung
Gilead Sciences Pty Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
EG-70 (phase 1)
Shanghai Antengene Corporation Limited
Superficial Bladder Cancer
1 trial -
EG-70-101
Shanghai Antengene Corporation Limited
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
EGFR-TK Inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nonsmall Cell Lung Cancer
1 trial -
EIK1001-008
Eikon Therapeutics
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
1 trial -
EIK1003-001
Eikon Therapeutics
Advance solid tumors
1 trial -
EIK1004 20mg Tablets, EIK1004 5mg Tablets
Eikon Therapeutics
Advanced solid tumors
1 trial -
EIK1004-001 (IMP1707-001)
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005-002
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
ELA-0121
Stemline Therapeutics B.V.
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
1 trial -
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma
1 trial -
ELVN-002-003
Enliven Therapeutics
Solid Tumors, Colorectal Cancer and Breast Cancer
1 trial -
EMB-01
Shanghai University of Traditional Chinese Medicine
Neoplasms
1 trial -
ENCORAFENIB , CETUXIMAB
The George Institute
Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.
1 trial -
ENGIC 01-COLOSOTO
CERO THERAPEUTICS HOLDINGS, INC.
colorectal cancer
1 trial -
ENHANCE
The George Institute
Intermediate risk prostate cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Ovarian Cancer
1 trial -
ENMD-2076
CASI Pharmaceuticals
Advanced Adult Hepatocellular Carcinoma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Triple Negative Breast Cancer
1 trial -
EOF5
Fudan University
Gastric Cancer
1 trial -
EORTC 1612-MG
Ningbo Cancer Hospital
BRAF V600 mutation–positive unresectable or metastatic melanoma
1 trial -
EORTC 1740-HNCG
Ningbo Cancer Hospital
Oropharyngeal Squamous Cell Carcinoma
1 trial -
EORTC-1745-ETF-BCG
Ningbo Cancer Hospital
Localized ER+ breast cancer
1 trial -
EP0042-101
Lacuna Pharma Pty Ltd
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
EP0062-101
Lacuna Pharma Pty Ltd
Breast Cancer
1 trial -
EPI-7386, Xtandi - 40 mg soft capsules
Lacuna Pharma Pty Ltd
Metastatic castration-resistant prostate cancer
1 trial -
ESR-17-13082
Disc Medicine
Locally advanced rectal cancer
1 trial -
ET-20-049
Lacuna Pharma Pty Ltd
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
ETOP 23-22 RAISE
Partner Therapeutics Limited
Extensive-disease small cell lung cancer and high SLFN11-expression
1 trial -
Elacestrant
Context Therapeutics
Breast Cancer
2 trials -
ElechtraPlatinum
Istituto Gentili S.r.l.
relapsing vulvar carcinoma already subjected to multiple treatments
1 trial -
Elironrasib
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Embrace-III Hi-Risk
Disc Medicine
high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer
1 trial -
EmpowHER 208
Jazz Pharmaceuticals Ireland Limited
HER2-positive breast cancer
1 trial -
Enasidenib
Agios Netherlands B.V.
Hematologic Neoplasms
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.